Risk Factors, Clinical Outcomes, and Cost-of-Care Related to Graft Failure in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients.

Holly Wobma,Zhezhen Jin,Susana Moscoso,Monica Bhatia,Larisa Broglie,Diane George,James Garvin,Prakash Satwani

Biology of Blood and Marrow Transplantation（2020）

引用 8|浏览28

暂无评分

摘要

•Graft failure was associated with alemtuzumab, reduced-intensity conditioning, and unrelated donor grafts.•Intermediate scheduling of alemtuzumab had the highest incidence of graft failure.•Costs and outcomes of graft failure have improved over time but remain a significant burden.

查看译文

关键词

Hematopoietic cell transplantation,Pediatrics,Graft failure,Neutropenic,Cost,Alemtuzumab,Campath,Reduced-intensity conditioning

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要